Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28650954 | 0.84 | GPR119 (0.41) | LMNAKMT2A | |
| SCHEMBL31488395 | 0.84 | GPR119 (0.41) | LMNAKMT2A | |
| SCHEMBL28650955 | 0.84 | GPR119 (0.41) | LMNAKMT2A | |
| SCHEMBL30186325 | 0.81 | GPR119 (0.33) | KMT2ASMN1; SMN2 | |
| SCHEMBL23523229 | 0.75 | LMNA (0.35) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23523231 | 0.75 | LMNA (0.35) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23523228 | 0.75 | LMNA (0.35) | LMNAHTTMEN1KMT2ASMN1; SMN2 | |
| Fumaric Acid SCHEMBL1177616 | 0.73 | SLC6A2 (0.44) | OPRK1LMNASMN1; SMN2 | |
| SCHEMBL25173818 | 0.73 | KCNH2 (0.38) | KCNH2OPRK1LMNA | |
| SCHEMBL20958512 | 0.73 | KCNH2 (0.38) | KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3921311-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163647-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | KCNH2 4684/4885OPRK1 2978/4885LMNA 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.